biostudies-literatureMooney BStand Up To CancerMichael Smith Health Research BCBC Cancer FoundationSt. Baldrick&apos;s FoundationNCI NIH HHSNational Institutes of HealthCancer Prevention and Research Institute of TexasCanadian Institutes of Health Research1022-1037https://www.ebi.ac.uk/biostudies/studies/S-EPMC10905525biostudies-literatureUnknown30(5)<h4>Purpose</h4>Ewing sarcoma is the second most common bone sarcoma in children, with 1 case per 1.5 million in the United States. Although the survival rate of patients diagnosed with localized disease is approximately 70%, this decreases to approximately 30% for patients with metastatic disease and only approximately 10% for treatment-refractory disease, which have not changed for decades. Therefore, new therapeutic strategies are urgently needed for metastatic and refractory Ewing sarcoma.<h4>Experimental design</h4>This study analyzed 19 unique Ewing sarcoma patient- or cell line-derived xenografts (from 14 primary and 5 metastatic specimens) using proteomics to identify surface proteins for potential immunotherapeutic targeting. Plasma membranes were enriched using density gradient uClinical cancer research : an official journal of the American Association for Cancer ResearchSurface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma.PMC10905525UO1CA263981SU2C-AACR-DT1113R35 CA2205001U54CA232568-01U01 CA263981R35CA220500RP160716T32 CA009140CA009140U54 CA23256841537718569RT-2023-3194Shraim RLizardo MMMaris JMSorensen PHMooney BDimitrov DSSpencer Miko SEEl-Naggar AMHoughton PJZhang HFDelaidelli ALi WKurmasheva RTHughes CSDiskin SJNegri GLShyp TWeiner AKMorin GBLi ARadaoui ABRouleau MfalseSurface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma.<h4>Purpose</h4>Ewing sarcoma is the second most common bone sarcoma in children, with 1 case per 1.5 million in the United States. Although the survival rate of patients diagnosed with localized disease is approximately 70%, this decreases to approximately 30% for patients with metastatic disease and only approximately 10% for treatment-refractory disease, which have not changed for decades. Therefore, new therapeutic strategies are urgently needed for metastatic and refractory Ewing sarcoma.<h4>Experimental design</h4>This study analyzed 19 unique Ewing sarcoma patient- or cell line-derived xenografts (from 14 primary and 5 metastatic specimens) using proteomics to identify surface proteins for potential immunotherapeutic targeting. Plasma membranes were enriched using density gradient u2024-01-01T00:00:00Z2024 Mar2026-06-08T06:07:57.377Z2025-05-29T20:46:31.097ZS-EPMC109055253781265210.1158/1078-0432.CCR-23-2187